Literature DB >> 3130927

Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine.

S Fogh1, A Schapira, I C Bygbjerg, S Jepsen, C H Mordhorst, K Kuijlen, P Ravn, A Rønn, P C Gøtzsche.   

Abstract

As malaria caused by Plasmodium falciparum has become resistant to chloroquine alternative drug regimens need to be developed. The prophylactic efficacy against malaria and the side effects of chloroquine phosphate 500 mg weekly with proguanil hydrochloride 200 mg daily was compared with the efficacy of chloroquine 500 mg weekly with sulfadoxine 500 mg-pyrimethamine 25 mg weekly in a randomised study of Scandinavian travellers to Kenya and Tanzania during 1984-5. A total of 767 subjects (416 male and 351 female; 384 taking chloroquine phosphate with proguanil hydrochloride and 383 taking chloroquine with sulfadoxine-pyrimethamine) completed a diary on the breakthrough of malaria and the side effects of treatment while taking the drugs. They were also asked to make thick blood films when symptoms like those of malaria occurred, which were sent to and analysed in Denmark. Four subjects taking chloroquine with proguanil hydrochloride and three taking chloroquine with sulfadoxine-pyrimethamine developed falciparum malaria, which was verified microscopically. Side effects were reported by 36 subjects taking chloroquine phosphate with proguanil hydrochloride and 55 taking the other regimen (p = 0.043). The side effects of both regimens were generally mild, but the combination of chloroquine phosphate with proguanil hydrochloride is recommended because it results in fewer side effects. As breakthroughs of malaria occurred at the earliest after seven weeks self treatment should not be recommended for travellers staying only a short time. Thick blood films are useful for diagnosis of suspected cases of malaria, can be prepared by non-specialists in Africa, and can be analysed successfully after long delays.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130927      PMCID: PMC2545106          DOI: 10.1136/bmj.296.6625.820

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  15 in total

1.  Malaria in the Australian army in South Vietnam: successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria.

Authors:  R H Black
Journal:  Med J Aust       Date:  1973-06-30       Impact factor: 7.738

2.  The susceptibility of Plasmodium falciparum to sulfadoxine and pyrimethamine: correlation of in vivo and in vitro results.

Authors:  A Schapira; I C Bygbjerg; S Jepsen; H Flachs; M W Bentzon
Journal:  Am J Trop Med Hyg       Date:  1986-03       Impact factor: 2.345

3.  Maloprim and agranulocytosis.

Authors:  L J Bruce-Chwatt; D B Hutchinson
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

4.  Pyrimethamine/dapsone resistant falciparum malaria imported from Kenya.

Authors:  C Herzog; H P Lambert; D Maudgal; D C Warhurst; R J Rogers
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

5.  Pyrimethamine/sulfadoxine resistant falciparum malaria acquired at Dar es Salaam, Tanzania.

Authors:  E Stahel; A Degrémont; U Lagler
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

6.  Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis.

Authors:  T E Peto; C F Gilks
Journal:  Lancet       Date:  1986-05-31       Impact factor: 79.321

7.  Concomitant resistance to pyrimethamine and cycloguanil of chloroquine-resistant falciparum malaria from East Africa: an in vitro study of 12 isolates.

Authors:  A Schapira
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

8.  Chloroquine-resistant Plasmodium falciparum malaria in Kenya.

Authors:  S Fogh; S Jepsen; P Effersøe
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

9.  Failure of malaria chemoprophylaxis with a proguanil-chloroquine combination in Papua New Guinea.

Authors:  A Henderson; J W Simon; W Melia
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

10.  Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya.

Authors:  W M Watkins; A D Brandling-Bennett; A J Oloo; R E Howells; H M Gilles; D K Koech
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more
  10 in total

Review 1.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2007-11-29

Review 2.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2010-07-12

Review 3.  Toxicity of antimalarial drugs.

Authors:  T E Peto
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 4.  Efficacy of drug prophylaxis.

Authors:  P A Phillips-Howard
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 5.  Extracts from "Clinical Evidence". Malaria: prevention in travellers.

Authors:  A Croft
Journal:  BMJ       Date:  2000-07-15

Review 6.  Prevention of malaria.

Authors:  J S Keystone
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 7.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Comparison of three regimens for malaria prophylaxis in travellers to east, central, and southern Africa.

Authors:  J C Wetsteyn; A de Geus
Journal:  BMJ       Date:  1993-10-23

9.  Validation of malaria surveillance case reports: implications for studies of malaria risk.

Authors:  P A Phillips-Howard; J Mitchell; D J Bradley
Journal:  J Epidemiol Community Health       Date:  1990-06       Impact factor: 3.710

10.  Chloroquine stimulates Cl- secretion by Ca2+ activated Cl- channels in rat ileum.

Authors:  Ning Yang; Zhen Lei; Xiaoyu Li; Junhan Zhao; Tianjian Liu; Nannan Ning; Ailin Xiao; Linlin Xu; Jingxin Li
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.